2003 NATIONAL SURVEY ON DRUG USE AND HEALTH

STATISTICAL INFERENCE REPORT

Prepared for the 2003 Methodological Resource Book

Authors:

Walter Boyle
James R. Chromy
Andrew Clarke
Teresa R. Davis
Steven L. Emrich
Erica Hirsch
Susan Hunter
Breda Munoz
Christine T. Murtha
Brian Newquist
Lisa E. Packer

Project Director: Thomas G. Virag

Prepared for:

Substance Abuse and Mental Health Services Administration
Rockville, Maryland 20857

Prepared by:

RTI International
Research Triangle Park, NC 27709

December 2004

2003 NATIONAL SURVEY ON DRUG USE AND HEALTH

STATISTICAL INFERENCE REPORT

RTI Project No. 7190
Contract No. 283-98-9008

Deliverable No. 28

Authors:

Walter Boyle
James R. Chromy
Andrew Clarke
Teresa R. Davis
Steven L. Emrich
Erica Hirsch
Susan Hunter
Breda Munoz
Christine T. Murtha
Brian Newquist
Lisa E. Packer

Project Director:
Thomas G. Virag

Prepared for:

Substance Abuse and Mental Health Services Administration
Rockville, MD 20857

Prepared by:

RTI International
Research Triangle Park, NC 27709

December 2004

Acknowledgments

Table of Contents

1. Introduction

Statistical inference occurs whenever data obtained from sample observations belonging to and considered representative of a larger target population are used to make generalizations concerning the larger population. The target population for the 2003 National Survey on Drug Use and Health (NSDUH)[1] was the U.S. civilian, non-institutionalized population aged 12 or older (at the time of their interview) in 2003. Measurements for this target population were the responses to the survey questions provided by persons participating in the 2003 survey.

Statistical inferences concerning characteristics of interest for this population are presented in the form of estimates derived from the sample data collected. Examples of the inferences made from the 2003 NSDUH data include estimates of the number of persons who were substance users during the past month, past year, and their lifetime, and the associated percentages (prevalence rates) of substance use for these reference periods. Inferences were also made for such categories as substance initiation, risk and protective factors, substance dependence and abuse, serious mental illness, and treatment for substance abuse and mental health. Among some populations of interest, sample sizes were not adequate to support inferences; in these cases, estimates were produced from annual averages based on combined data from the 2002 and 2003 NSDUHs.

This report is organized as follows: Section 2 provides background information concerning the 2003 NSDUH; Sections 3 and 4 discuss the prevalence rates and sampling errors and how they were calculated; Section 5 describes the degrees of freedom that were used when comparing estimates; and Section 6 discusses how statistical significance of differences between estimates was determined. Section 7 discusses confidence interval estimation and Section 8 describes how the rates for initiation or incidence of drug use were computed. Finally, Section 9 discusses the conditions under which estimates with low precision were suppressed.

---

[1] Prior to 2002, the survey was called the National Household Survey on Drug Abuse (NHSDA).

2. Background

From 1999 through 2003, the National Survey on Drug Use and Health (NSDUH) was implemented as part of a coordinated 5-year, 50-State sample design to provide national and State estimates of drug use. The introduction of computer-assisted interviewing (CAI) methods for the screening and interviewing of selected respondents was a substantial change implemented at the beginning of the 5-year study protocol.

For the 5-year, 50-State design, eight States were designated as large sample States: California, Florida, Illinois, Michigan, New York, Ohio, Pennsylvania, and Texas. The samples collected from each of these states were large enough to support direct State estimates. In 2003, sample sizes in the eight large States ranged from 3,541 to 3,711. For the remaining 42 States and the District of Columbia, smaller samples were selected, but these were sufficient to support State estimates using small area estimation (SAE) techniques. Sample sizes in these small States ranged from 856 to 964 in 2003.

In the 50-State design, the geographic area as a whole was first stratified into a total of 900 field interviewer (FI) regions (48 regions in each large sample State and 12 regions in each small sample State). Within FI regions, adjacent Census blocks were combined to form the first-stage sampling units called "segments." Eight sample segments per FI region were fielded during the 2003 survey year. These sampled segments were allocated equally into four separate samples, one for each 3-month period during the year, so that the survey remained in the field in each FI region year-round.

Several substantial survey design changes were implemented during the 2002 NSDUH, and these modifications were continued in the 2003 survey. The use of a $30 respondent incentive[2] was implemented based on the results of an experimental incentive study conducted during the 2001 survey. Also, the name of the survey was changed from the National Household Survey on Drug Abuse (NHSDA) to the current name, National Survey on Drug Use and Health (NSDUH). Both of these changes may have contributed to the increase in respondent cooperation. The last change implemented was an increase in the number of pairs selected in dwelling units where a person aged 26 or older was on the roster, which led to an increase in the total number of pairs selected.[3] Since these changes may impact both the response rates and the quality of the data, current and future NSDUH estimates can no longer be compared with estimates from NHSDAs prior to 2002.

The final respondent sample of 67,784 persons for the 2003 NSDUH provides a sufficient sample to create domain estimates for a broad range of ages and other demographic categories. Further, individual observations are weighted in a manner such that the weighted sample is

---

[2] For more information on the implications and use of respondent incentives in the NSDUH, please see the *2001 National Household Survey on Drug Abuse: Incentive experiment: Combined quarter 1 and quarter 2 analysis* (Eyerman and Bowman, 2002).

[3] For more information on the increase in the total number of pairs selected in the NSDUH please see the Sample Design Report in the *2003 National Survey on Drug Use and Health: Methodological resource book* (Bowman, Chromy, Hunter, and Martin, 2005).

representative of the civilian, non-institutionalized population aged 12 or older for both the general U.S. population as well as for each of the individual States.

3. Prevalence Rates

The national prevalence rates were computed using a multiprocedure package, SUrvey DAta ANalysis (SUDAAN) Software for Statistical Analysis of Correlated Data (RTI, 2001). The final, nonresponse-adjusted, and poststratified analysis weights were used in SUDAAN to compute unbiased design-based drug use estimates.

Prevalence rates are the proportions of the population who exhibit characteristics of interest (such as substance use). Let $\hat{p}_d$ represent the prevalence rate of interest for domain d. Then $\hat{p}_d$ would be defined as the ratio

$$\hat{p}_d = \frac{\hat{Y}_d}{\hat{N}_d},$$

where $\hat{Y}_d$ = estimated number of persons exhibiting the characteristic of interest in domain d, and $\hat{N}_d$ = estimated population total for domain d.

$\hat{N}_d$ is estimated as $\sum w_i \delta_i$, where w_i represents the analysis weight and δ_i represents an indicator variable, which is defined as:

$\delta_i\ (d) =$ 1 if the ith sample unit is in subgroup d,
                      0 otherwise.

For certain populations of interest, the 2002 and 2003 data were combined to obtain annual averages and then the prevalence rates were computed in SUDAAN as described above. The annual averages were derived by concatenating the 2002 and 2003 datasets and then dividing the analysis weights by a factor of 2.

4. Sampling Error

Like the prevalence rates, all of the variance estimates (including those for prevalence rates based on annual averages from combined data) were calculated using a method in SUDAAN that is unbiased for linear statistics based on multistage clustered sample designs where the first-stage (primary) sampling units are drawn with replacement.

Due to the complex nature of the National Survey on Drug Use and Health (NSDUH) sampling design (specifically the use of stratified-clustering sampling), key nesting variables were created for use in SUDAAN to capture explicit stratification and to identify clustering. For the 2003 NSDUH, each field interviewer (FI) region was considered its own stratum with two replicates defined within each variance stratum (FI region). The first replicate consisted of those "phasing out" segments (i.e., those which would not be used in the next survey year). The second replicate was made up of those "phasing in" segments (i.e., those which would be fielded again the following year), thus constituting the 50 percent overlap between survey years. Each variance replicate consisted of four segments, one segment for each quarter of data collection.

Estimates of means or proportions, $\hat{p}_d$, such as drug use prevalence rates, take the form of nonlinear statistics whenever the variances cannot be expressed in closed form. Variance estimation for nonlinear statistics in SUDAAN is performed using a first-order Taylor series approximation of the deviations of estimates from their expected values (RTI, 2001).

Estimates of domain totals, $\hat{Y}_d$, corresponding to estimates of domain means or proportions, $\hat{p}_d$, can be estimated as

$$\hat{Y}_d = \hat{N}_d \cdot \hat{p}_d,$$

where $\hat{N}_d$ = estimated population total for domain d, and $\hat{p}_d$ = estimated mean or proportion for domain d.

The standard error (SE) for the total estimate is obtained by multiplying the SE of the mean or proportion by $\hat{N}_d$, that is,

$$SE(\hat{Y}_d) = \hat{N}_d \cdot SE(\hat{p}_d).$$

This approach is theoretically correct when the domain size estimates, $\hat{N}_d$, are among those forced to Census Bureau population projections through the weight calibration process (Chen, Dai, Gordek, Shi, Singh, & Westlake, 2005). In these cases, $\hat{N}_d$ is not subject to sampling error.

For estimated domain totals, $\hat{Y}_d$, where $\hat{N}_d$ is not fixed (i.e., where domain size estimates are not forced to Census Bureau population projections), this formula may still provide a good

approximation if it can be reasonably assumed that the sampling variation in $\hat{N}_d$ is negligible relative to the sampling variation in $\hat{p}_d$. For most NSDUH estimates, this is a reasonable assumption.

However, for a subset of tables produced from the 2003 data, the above approach yielded an underestimate of the variance of a total because $\hat{N}_d$ was subject to considerable variation. In these cases, a direct estimate of the standard error of $\hat{Y}_d$ was taken from SUDAAN.

5. Degrees of Freedom

To determine whether the observed difference between estimates is statistically significant, the degrees of freedom are needed to locate the corresponding probability level (p value) of the test statistic. The test statistic is computed from the sample data and represents a numerical summary of the difference between the estimates under consideration; it is a random variable that has a predetermined distribution (such as normal, chi-square, or F). The "degrees of freedom" characterize the amount of variation expected in the estimation of sampling error and are used in conjunction with the test statistic to determine probabilities and evaluate statistical significance.

The degrees of freedom are calculated as the number of primary sampling units (variance replicates) less the number of strata for the data being analyzed. In National Survey on Drug Use and Health (NSDUH) analyses, the degrees of freedom are based on the first-level stratification (i.e., the field interviewer [FI] regions). When producing NSDUH estimates on the national level, including estimates based on annual averages from combined data, there are 900 degrees of freedom. If an analysis only involves certain States, the degrees of freedom change depending on whether the State is a large sample or small sample State. The large sample States each have 48 degrees of freedom. All other States (small sample States and the District of Columbia) have 12 degrees of freedom. For specific State analyses (or other subpopulations of interest), the degrees of freedom can be specifically indicated in SUDAAN; otherwise the degrees of freedom are computed using the entire dataset.

6. Statistical Significance of Differences

Once the degrees of freedom have been determined, various methods used to compare prevalence estimates may be employed. This section describes some of these methods. Customarily, the observed difference between estimates is evaluated in terms of its statistical significance. Statistical significance is based on the *p* value of the test statistic, and refers to the probability that a difference as large as that observed would occur due to random variability in the estimates if there were no difference in the prevalence rates being compared. The significance of observed differences is generally reported at the 0.05 and 0.01 levels.

Significance tests were conducted on differences between prevalence estimates from the 2002 and 2003 National Surveys on Drug Use and Health (NSDUHs); in addition, within-year tests were conducted on differences between prevalence estimates for various populations (or subgroups) of interest using data from the 2003 survey. No significance tests were conducted on prevalence estimates based on annual averages derived from the combined 2002 and 2003 survey data. Due to survey design changes implemented in 2002, data from the 2002 and 2003 NSDUHs should not be compared to data from earlier survey years.

When comparing prevalence estimates, one can test the null hypothesis (no difference between rates) against the alternative hypothesis (there is a difference in prevalence rates) using the standard t-test (with the appropriate degrees of freedom) for the difference in proportions, expressed as

$$t_{df} = \frac{\hat{p}_1 - \hat{p}_2}{\sqrt{\text{var}(\hat{p}_1) + \text{var}(\hat{p}_2) - 2\,\text{cov}(\hat{p}_1, \hat{p}_2)}},$$

where df = the appropriate degrees of freedom, $\hat{p}_1$ = first prevalence estimate, $\hat{p}_2$ = second prevalence estimate, $\text{var}(\hat{p}_1)$ = variance of first prevalence estimate, $\text{var}(\hat{p}_2)$ = variance of second prevalence estimate, and $\text{cov}(\hat{p}_1, \hat{p}_2)$ = covariance between $\hat{p}_1$ and $\hat{p}_2$. Note that the first and second prevalence estimates may either be prevalence estimates from 2002 and 2003, respectively, or prevalence estimates for populations of interest from 2003.

Under the null hypothesis, *t* is distributed as a random variable from the *t*-distribution. Therefore, calculated values of *t*, along with the appropriate degrees of freedom, can be used to determine the corresponding probability level (i.e., *p* value). Whether testing for differences between years or from different populations within the same year, the covariance term in the formula for *t* will, in general, not be equal to 0. SUDAAN is used to compute estimates of *t* along with the associated *p* values such that the covariance term is calculated by taking the sample design into account. A similar procedure and formula for *t* are used for estimated totals.

As the degrees of freedom approach infinity, the *t* distribution approaches the standard normal (Z) distribution. That is, since most of the statistical tests performed have 900 degrees of freedom, the *t* tests performed produce approximately the same numerical results as if a Z test had been performed.

When comparing population subgroups defined by three or more levels of a categorical variable, log-linear Chi-square tests of independence of the subgroup and the prevalence variables were conducted first to control the error level for multiple comparisons. If the Chi-square test indicated overall significant differences, the significance of each particular pairwise comparison of interest was tested using SUDAAN analytic procedures to properly account for the sample design. A detailed description of the test statistic, which is based on the Wald statistic, can be found in the SUDAAN user's manual (RTI, 2001, pp. 317-319).

7. Confidence Intervals

In some National Survey on Drug Use and Health (NSDUH) publications, sampling error was quantified using 95 percent confidence intervals. Because the estimates in the NSDUH are frequently small percentages, the confidence intervals are based on logit transformations. Logit transformations yield asymmetric interval boundaries that are more balanced with respect to the probability that the true value falls below or above the interval boundaries than is the case for standard symmetric confidence intervals for small proportions.

To illustrate the method, let the proportion P_d represent the true prevalence rate for a particular analysis domain d. Then, the logit transformation of P_d, commonly referred to as the "log odds," is defined as

$$L = \ln[P_d / (1 - P_d)],$$

where "ln" denotes the natural logarithm.

Letting $\hat{p}_d$ be the estimate of the domain proportion, the log odds estimate becomes

$$\hat{L} = \ln[\hat{p}_d / (1 - \hat{p}_d)].$$

The lower and upper confidence limits of L are formed as

$$A = \hat{L} - K\left[\frac{\sqrt{\mathrm{var}(\hat{p}_d)}}{\hat{p}_d(1 - \hat{p}_d)}\right],$$

$$B = \hat{L} + K\left[\frac{\sqrt{\mathrm{var}(\hat{p}_d)}}{\hat{p}_d(1 - \hat{p}_d)}\right],$$

where $\mathrm{var}(\hat{p}_d)$ is the variance estimate of $\hat{p}_d$, the quantity in brackets is a first-order Taylor series approximation of the standard error (SE) of $\hat{L}$, and K is the constant chosen to yield a level of confidence based on the degrees of freedom (e.g., $K = 1.96$ for 95 percent confidence limits for national estimates with 900 degrees of freedom).

Applying the inverse logit transformation to A and B above yields a confidence interval for $\hat{p}_d$ as follows:

$$\hat{p}_{d,lower} = \frac{1}{1 + \exp(-A)},$$

$$\hat{p}_{d,upper} = \frac{1}{1 + \exp(-B)},$$

where "exp" denotes the inverse log transformation. The lower and upper confidence interval endpoints for percentage estimates are obtained by multiplying the lower and upper endpoints of $\hat{p}_d$ by 100.

The confidence interval for the estimated domain total, $\hat{Y}_d$, as estimated by

$$\hat{Y}_d = \hat{N}_d \cdot \hat{p}_d,$$

is obtained by multiplying the lower and upper limits of the proportion confidence interval by $\hat{N}_d$. For domain totals $\hat{Y}_d$, where $\hat{N}_d$ is not fixed, the confidence interval approximation assumes that the sampling variation in $\hat{N}_d$ is negligible relative to the sampling variation in $\hat{p}_d$.

8. Incidence Estimates

To assist in the evaluation of trends in the initiation of drug use, National Survey on Drug Use and Health (NSDUH) data also were used to generate estimates of drug use incidence or initiation (i.e., the number of new users during a given year). Incidence rates measure the rapidity with which new drug users arise and can suggest emerging patterns of drug use.

The measure of incidence is defined as the number of new cases of drug initiation divided by the person time of exposure. For diseases, the incidence rate, *IR*, for a population is defined as the number of new cases of the disease, *N*, divided by the person time, *PT*, of exposure, or

$$IR = \frac{N}{PT}.$$

The person time of exposure is measured as the net time that individuals in the population during an observed period of time are at risk of developing the disease. This period of time can be for the full period of the study or for a shorter period. The person time of exposure ends at the time of diagnosis (e.g., Greenberg, Daniels, Flanders, Eley, & Boring, 1996, pp. 16-19). Similar conventions were followed for defining the incidence of first use of a substance.

Beginning in 1999, the NSDUH questionnaire allowed for the collection of year and month of first use for recent initiates. The month, day, and year of birth for the initiates were also obtained directly or imputed during the processing of the data. In addition, the questionnaire call record provided the date of the interview. By imputing a day of first use within the year and month of first use reported or imputed, the key respondent inputs, in terms of exact dates, can be computed. Exposure time can be determined in terms of days and converted to an annual value. Beginning in 2003, the immigrant population was addressed in the incidence analysis. That is, immigrants who initiated drug use outside the United States were not included in the analysis. However, those immigrants who did not initiate outside the United States were included in the analysis for the time period since they entered the United States. If respondents indicated that they were not born in the United States, the survey questionnaire asked the respondent how long they had lived in the United States. Using this information, an imputation-revised entry age and date were created.

Having exact dates of birth and first use (and, if the respondent is an immigrant, his or her exact date of entry) also allowed the person time of exposure during the targeted period, *t*, to be determined. Let the target time period for measuring incidence be specified in terms of dates; for example, the period 1998 would be specified as

$$t = [t_1, t_2) = [1 \text{ Jan } 1998, 1 \text{ Jan } 1999),$$

a period that includes January 1, 1998, and all days up to but not including January 1, 1999. The target age group can also be defined by a half-open interval as $a = [a_1, a_2)$. For example, the age group 12 to 17 would be defined by $a = [12,18)$ for youths at least age 12, but not yet age 18.

If person i was in age group a and residing in the United States during period t, the time and age interval, $L_{t,a,i}$, can then be determined by the intersection

$$L_{t,a,i} = [t_1, t_2) \cap \{[DOB_iMOB_iYOB_i + a_1, DOB_iMOB_iYOB_i + a_2) \cap [I_{\{US\ Born, Immigrant\}}(i), \infty)\},$$

where the time of birth and time of entry into the United States is defined in terms of day (DOB_i and DOE_i), month (MOB_i and MOE_i), and year (YOB_i and YOE_i), and

$$I_{\{US\ Born,\ Immigrant\}}(i) = \quad DOB_iMOB_iYOB_i \text{ if } i \text{ is US Born,}$$
$$DOE_iMOE_iYOE_i \text{ if } i \text{ is an Immigrant.}$$

Either this intersection was empty ($L_{t,a,i} = \varnothing$), or it was defined by the half-open interval, $L_{t,a,i} = [m_{1,i}, m_{2,i})$, where

$$m_{1,i} = Max\{t_1, (DOB_iMOB_iYOB_i + a_1), DOE_iMOE_iYOE_i\},$$

and

$$m_{2,i} = Min\{t_2, (DOB_i\ MOB_i\ YOB_i + a_2)\}.$$

The date of first use, $t_{fu,d,i}$, is also expressed as an exact date. An incident of first use of drug d by person i in age group a occurs in time t if $t_{fu,d,i} \in [m_{1,i}, m_{2,i})$. The indicator function, $I_i(d,a,t)$, used to count incidents of first use is set to 1 when $t_{fu,d,i} \in [m_{1,i}, m_{2,i})$, and to 0 otherwise. The person time of exposure, measured in years and denoted by $e_i(d,a,t)$ for a person i of age group a depends on the date of first use. If the date of first use precedes the target period ($t_{fu,d,i} < m_{1,i}$), then $e_i(d,a,t) = 0$. If the date of first use occurs after the target period or if person i has never used drug d, then

$$e_i(d,a,t) = \frac{m_{2,i} - m_{1,i}}{365}.$$

If the date for first use occurs during the target period, $L_{t,a,i}$, then

$$e_i(d,a,t) = \frac{t_{fu,d,i} - m_{1,i}}{365}.$$

During leap years, the denominator used to compute person time of exposure is set to 366. Note that both $I_i(d,a,t)$ and $e_i(d,a,t)$ are set to 0 if the target period, $L_{t,a,i}$, is empty (i.e., person i is not in age group a during time t). The incidence rate is then estimated as a weighted ratio estimate

$$IR(d,a,t) = \frac{\sum_i w_i I_i(d,a,t)}{\sum_i w_i e_i(d,a,t)},$$

where w_i is the respondent's analytic weight for 2003.

Since the incidence estimates are based on retrospective reports by survey respondents, as was the case for earlier estimates, the estimates may be subject to the same kinds of biases. Differential mortality bias occurs since some persons who were exposed to the risk of first drug use in historical periods died before the 2002 or 2003 NSDUH surveys were conducted. This type of bias is probably very small. Incidence estimates are also affected by memory errors, including recall decay (tendency to forget events occurring long ago) and forward telescoping (tendency to report that an event occurred more recently than it actually did). Recall decay would tend to result in a downward bias in estimates for earlier years (i.e., 1960s and 1970s), and telescoping would tend to result in an upward bias for estimates in more recent years. There is also likely to be some underreporting bias because of the social stigma of drug use behaviors and respondents' fears of disclosure. This bias is likely to have the greatest impact on recent estimates which reflect more recent use and reporting by younger respondents. Finally, for drug use that is frequently initiated at age 10 or younger, estimates based on 1-year retrospective reports underestimate total incidence since children 11 years old and younger are not sampled by the NSDUH. Prior analyses showed that alcohol and cigarette (any use) incidence estimates could be significantly affected by this. Therefore, for these drugs, only 2002 age-specific rates and the number of initiates 18 or older (or 21 or over for applicable tables) were reported.

A recent evaluation of NSDUH retrospective estimates of incidence suggests that these type of bias are significant and differ by substance and length of recall (Gfroerer, Hughes, Chromy, Heller, & Packer, 2004). For very recent time periods, bias in estimates of marijuana, cocaine, alcohol, and cigarettes appear to be small, but for all other substances there is significant downward bias. Bias for all substances increases the further back in time the estimates are made, suggesting a relationship with the length of recall. Due to the potential reporting biases described above, comparisons between years, particularly between recent estimates and those 10 or more years prior, should be made with caution.

9. Suppression of Estimates with Low Precision

Direct survey estimates that were considered to be unreliable due to unacceptably large sampling errors were not reported, but rather were noted by an asterisk (*). The criterion used for suppressing all direct survey estimates was based on the relative standard error (RSE), which is defined as the ratio of the standard error (SE) over the estimate.

Proportion estimates $(\hat{p})$ within the range $0 < \hat{p} < 1,$ rates, and corresponding estimated numbers of users were suppressed if

$$\text{RSE}\ [-\ln(\hat{p})] > 0.175 \text{ when } \hat{p} \le 0.5,$$
$$\text{or}$$
$$\text{RSE}\ [-\ln(1-\hat{p})] > 0.175 \text{ when } \hat{p} > 0.5.$$

Based on a first-order Taylor series approximation of RSE $[-\ln(\hat{p})]$ and RSE $[-\ln(1-\hat{p})],$ the following suppression rule was used for computational purposes:

$$\frac{\text{SE}(\hat{p})/\hat{p}}{-\ln(\hat{p})} > 0.175 \text{ when } \hat{p} \le 0.5,$$
$$\text{or}$$
$$\frac{\text{SE}(\hat{p})/(1-\hat{p})}{-\ln(1-\hat{p})} > 0.175 \text{ when } \hat{p} > 0.5.$$

The separate formulas for $\hat{p} \le 0.5$ and $\hat{p} > 0.5$ produce a symmetric suppression rule; that is, if $\hat{p}$ is suppressed, $1-\hat{p}$ will be suppressed as well. See Figure 1 for a graphical representation of the required minimum effective sample sizes as a function of the proportion estimated. When $0.05 < \hat{p} < 0.95,$ the symmetric properties of the rule produce local minimum effective sample sizes at $\hat{p} = 0.2$ and again at $\hat{p} = 0.8,$ such that an effective sample size of greater than 50 is required; this means that estimates would be suppressed for these values of $\hat{p}$ unless the effective sample sizes were greater than 50. Within this same interval of $0.05 < \hat{p} < 0.95,$ a local maximum effective sample size of 68 is required at $\hat{p} = 0.5.$ So, to simplify requirements and maintain a conservative suppression rule, estimates of $\hat{p}$ between 0.05 and 0.95 which had effective sample sizes below 68 were suppressed.

Figure 1.   Required Effective Sample as a Function of the Proportion Estimated

A minimum nominal sample size suppression criterion ($n = 100$) that protects against unreliable estimates caused by small design effects and small nominal sample sizes was employed. Prevalence estimates were also suppressed if they were close to 0 or 100 percent (i.e., if $\hat{p} < 0.00005$ or if $\hat{p} \geq 0.99995$).

Estimates of other totals (e.g., number of initiates), along with means and rates not bounded between 0 and 1 (e.g., mean age at first use and incidence rates) were suppressed if the RSEs of the estimates were larger than 0.5.

Additionally, estimates of mean age of first use were suppressed if the sample sizes were smaller than 10 respondents; also, the estimated incidence rate and number of initiates were suppressed if they rounded to 0.

The suppression criteria for various NSDUH estimates are summarized in Table 1.

Table 1. Summary of 2003 NSDUH Suppression Rules

Estimate	Suppress if:
Prevalence rate, $\hat{p}$, with nominal sample size, n, and design effect, *deff*	(1) The estimated prevalence rate, $\hat{p}$, is less than 0.00005 or greater than or equal to 0.99995, or (2) $\dfrac{\mathrm{SE}(\hat{p})/\hat{p}}{-\ln(\hat{p})} > 0.175$ when $\hat{p} \leq 0.5$, or $\dfrac{\mathrm{SE}(\hat{p})/(1-\hat{p})}{\ln(1-\hat{p})} > 0.175$ when $\hat{p} > 0.5$, or (3) Effective $n < 68$, where Effective $n = \dfrac{n}{deff}$, or (4) $n < 100$. Note: The rounding portion of this suppression rule for prevalence rates will produce some estimates that round at one decimal place to 0.0 percent or 100.0 percent but are not suppressed from the tables.
Estimated number (numerator of $\hat{p}$)	The estimated prevalence rate, $\hat{p}$, is suppressed. Note: In some instances when $\hat{p}$ is not suppressed, the estimated number may appear as a 0 in the tables; this means that the estimate is greater than 0 but less than 500 (estimated numbers are shown in thousands).
Mean age at first use, $\bar{x}$, with nominal sample size, n	(1) $\mathrm{RSE}(\bar{x}) > 0.5$, or (2) $n < 10$
Incidence rate, $\hat{r}$	(1) The incidence rate, $\hat{r}$, rounds to less than 0.1 per thousand person years of exposure, or (2) $\mathrm{RSE}(\hat{r}) > 0.5$
Number of initiates, $\hat{t}$	(1) The number of initiates $\hat{t}$, rounds to fewer than 1,000 initiates, or (2) $\mathrm{RSE}(\hat{t}) > 0.5$

References

Bowman, K. R., Chromy, J. R., Hunter, S. R., & Martin, P.C.(2005). Sample design report. In *2003 National Survey on Drug Use and Health: Methodological resource book* (prepared for the Substance Abuse and Mental Health Services Administration, Contract No. 283-98-9008). Research Triangle Park, NC: RTI.

Chen, P., Dai, L., Gordek, H., Shi, W., Singh, A., & Westlake, M. (2005). Sampling weight calibration for the 2003 NHSDA. In *2003 National Survey on Drug Use and Health: Methodological resource book* (prepared for the Substance Abuse and Mental Health Services Administration, Contract No. 283-98-9008). Research Triangle Park, NC: RTI.

Eyerman, J., & Bowman, K. (2002). *2001 National Household Survey on Drug Abuse: Incentive experiment: Combined quarter 1 and quarter 2 analysis* (prepared for the Substance Abuse and Mental Health Services Administration, Contract No. 283-98-9008). Research Triangle Park, NC: RTI.

Gfroerer, J., Hughes, A., Chromy, J., Heller, D., & Packer, L. (2004, July). Estimating trends in substance use based on reports of prior use in a cross-sectional survey. In S. B. Cohen & J. M. Lepkowski (Eds.), *Eighth Conference on Health Survey Research Methods* (DHHS Publication No. PHS 04-1013, pp. 29-34). Hyattsville, MD: National Center for Health Statistics. [Available as a PDF at http://www.cdc.gov/nchs/data/misc/proceedings_hsrm2004.pdf]

Greenberg, R. S., Daniels, S. R., Flanders, W. D., Eley, J. W., & Boring, J. R. (1996). *Medical epidemiology.* Norwalk, CT: Appleton & Lange.

Research Triangle Institute. (2001). SUDAAN *user's manual*: *Release 8.0*. Research Triangle Park, NC: Author.